TRANSMEDICS GROUP INC (TMDX)
Health Care · Organ preservation and transplant technology · NASDAQ
TransMedics commercializes the only FDA-approved portable warm perfusion platform for multi-organ transplantation, replacing cold storage to dramatically increase donor organ utilization and post-transplant outcomes.
What TRANSMEDICS GROUP INC does
TransMedics is a medical technology company that develops and commercializes the Organ Care System (OCS), a warm perfusion platform for preserving and optimizing donor organs (heart, lung, and liver) outside the human body before transplantation. The company also operates the National Organ Program (NOP), which provides turnkey organ procurement, OCS management, and transplant logistics services to U.S. transplant centers. The OCS replaces cold storage by maintaining organs in a living, functioning state with oxygenated blood, significantly improving organ utilization rates and post-transplant outcomes.
Themes: ["organ preservation / transplantation","warm perfusion technology","medical devices","end-stage organ failure treatment","organ viability assessment","donor organ utilization","transplant logistics"]
Fundamentals
- Price$72.19 as of 2026-07-09 close
- Market cap$2.5B as of 2026-07-10
- 1-year return-42.9% as of 2026-07-09 close
- P/E14.66 as of 2026-07-10
- Net margin+27.0% as of 2026-07-10
- Gross margin+59.1% as of 2026-07-10
- ROE+41.9% as of 2026-07-10
- Debt / equity1.73 as of 2026-07-10
- Revenue growth (YoY)+30.2% as of 2026-07-10
- Revenue CAGR (3y)+86.4% SEC XBRL
- Beta1.94 as of 2026-07-10
Key risks (from latest filing)
["Regulatory risk: dependence on FDA approval and Pre-Market Approval (PMA) status for all OCS products; changes in regulatory pathways could impact market access","Market adoption risk: transplant centers must adopt the OCS and NOP services instead of traditional cold storage; adoption rates and market penetration are critical to revenue growth","Competitive and reimbursement risk: pressure from cold storage incumbency, competing organ preservation technologies, and uncertainty around insurance coverage and reimbursement rates for OCS and NOP services"]
Competitors & peers
- CartiHeal (cartilage regeneration; not direct competitor but in transplant/tissue space)
- Preservation Solutions (organ preservation technologies)
- hypothermosol (cold storage preservation solutions — incumbent standard of care)
- Legacy cold storage and static preservation systems (incumbent competitors)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.